RNeasy Mini Kit

High-quality total RNA in minutes.

Investigator 24plex QS Kit

Multiplex amplification for human ID, with CODIS and European standard markers.

QIAsphere

Monitor and manage your QIAsphere-ready instruments from anywhere, using any mobile device.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Find out more

QIAGENbioinformatics.com

COVID-19 testing and research

Up to date protocols and list of COVID-19 testing and research solutions.

RNeasy Mini Kit

High-quality total RNA in minutes.

Smart ideas, deep insights

Get inspiring content today – with a free face mask.

QuantiFERON-TB Gold Plus

Detect TB infection with confidence.

QIAGEN Clinical Insight (QCI) Interpret

Transparent, evidence-based NGS interpretation and reporting.

Press Release

Home  >  Newsroom  >  Press Releases  >  Press Release Details
View all news

QIAGEN commits to reduce carbon emissions by setting science-based target to reach net zero by 2050

November 8, 2021
  • Joins “Business Ambition for 1.5˚C” campaign of the Science-Based Targets initiative
  • Commitment to achieve by 2030 at least 40% reduction in Scope 1 and 2 emissions, and at least 10% reduction in Scope 3 emissions, on way to reach net-zero carbon emissions by 2050

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its commitment to a science-based target of net-zero carbon emissions by 2050 in order to help limit global warming to 1.5˚C. This move supports the goals set out by the Paris Climate Agreement and marks an important milestone in QIAGEN’s sustainability efforts.

QIAGEN’s ambition to reach net-zero by 2050 applies to its entire value chain and fulfills the criteria of the Science-Based Targets initiative (SBTi), a partnership between the non-profit disclosure specialist CDP, United Nations Global Compact (UNGC), World Resources Institute (WRI) and World Wide Fund for Nature (WWF).

The commitment calls for QIAGEN by 2030 to reduce Scope 1 and 2 emissions by at least 40% and Scope 3 emissions by at least 10% on the way to reaching net-zero carbon emissions by 2050 using 2020 as a baseline.

QIAGEN is joining more than 2,000 companies and other groups in the United Nations’ Race to Zero Campaign anchored through SBTi’s “Business Ambition for 1.5˚C” initiative.

“Our commitment strengthens QIAGEN’s ambition to reduce carbon emissions and do our part to hold global warming to 1.5˚C compared to pre-industrial times. Helping to create a sustainable future is at the core of our vision of making improvements in life possible,” said Thierry Bernard, Chief Executive Officer of QIAGEN N.V. “Social and environmental responsibility are vital to our business. In pledging to become carbon neutral by 2050, we are taking these commitments to the next level and embedding environmental sustainability in everything we do.”

QIAGEN plans to achieve net zero status by cutting direct and indirect emissions throughout its operations. This goal is planned to be achieved through a series of measures - including transitioning facilities to renewable energy, implementing energy-saving measures, minimizing waste in operations, factoring carbon footprints into product development, and working with suppliers and logistical operators to reduce their carbon footprints.

A shrinking carbon footprint is just one key aspect of QIAGEN’s sustainability initiatives, which are reflected in QIAGEN having a PRIME rating from ISS ESG. Other aspects include a pledge to cut plastic use in packaging for products, a steadfast dedication to being socially responsible toward communities, and unwavering support for creating a diverse and inclusive working environment.

“Factoring social and environmental problems into day-to-day business is not about putting up with them as best-avoided costs that only add to the price of doing business,” said Dr. Angelika Storm, Head of ESG Strategy and Impact Programs at QIAGEN. “It is about recognizing them as an investment into being able to continue operating as a company.”

For more information on QIAGEN’s sustainability initiatives, please visit our website at https://www.qiagen.com/us/sustainability.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare), Applied Testing (primarily forensics), Pharma (pharma and biotech companies) and Academia (life sciences research). As of September 30, 2021, QIAGEN employed approximately 6,000 people in over 35 locations worldwide. Further information can be found at http://www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, collaborations markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC).

Multimedia Files:

View all news